Supreme Court Unanimously Rules on Pharmaceutical Patent Dispute, Clarifying Legal Standards
The Supreme Court delivered a unanimous decision in the case of Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., authored by Justice Ketanji Brown Jackson. The ruling reversed a lower court's decision, sending the case back for further proceedings. This decision is significant as it clarifies how courts should evaluate whether generic drugmakers can be sued for inducing patent infringement when marketing medicines with 'skinny labels' that exclude patented uses. This clarification may impact how lower-cost drugs are introduced to the market. The unanimous decision is notable given the court's often perceived ideological divisions, highlighting a rare moment of full agreement among the justices. 
